SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cyclacel Pharmaceuticals, Inc. Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients With Myelodysplastic Syndromes